{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T18:20:28Z","timestamp":1790706028443,"version":"4.1.0"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,1,18]],"date-time":"2018-01-18T00:00:00Z","timestamp":1516233600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,1,18]],"date-time":"2018-01-18T00:00:00Z","timestamp":1516233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Malaria, caused by parasites of the genus <jats:italic>Plasmodium<\/jats:italic>, leads to over half a million deaths per year, 90% of which are\u00a0caused by <jats:italic>Plasmodium falciparum<\/jats:italic>. <jats:italic>P<\/jats:italic>. <jats:italic>vivax<\/jats:italic> usually causes milder forms of malaria; however, <jats:italic>P<\/jats:italic>. <jats:italic>vivax<\/jats:italic> can remain dormant in the livers of infected patients for weeks or years before re-emerging in a new bout of the disease. The only drugs available that target all stages of the parasite can lead to severe side effects in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency; hence, there is an urgent need to develop new drugs active against blood and liver stages of the parasite. Different groups have demonstrated that triclosan, a common antibacterial agent, targets the <jats:italic>Plasmodium<\/jats:italic> liver enzyme enoyl reductase. Here, we provide 4 independent lines of evidence demonstrating that triclosan specifically targets both wild-type and pyrimethamine-resistant <jats:italic>P<\/jats:italic>. <jats:italic>falciparum<\/jats:italic> and <jats:italic>P<\/jats:italic>. <jats:italic>vivax<\/jats:italic> dihydrofolate reductases, classic targets for the blood stage of the parasite. This makes triclosan an exciting candidate for further development as a dual specificity antimalarial, which could target both liver and blood stages of the parasite.<\/jats:p>","DOI":"10.1038\/s41598-018-19549-x","type":"journal-article","created":{"date-parts":[[2018,1,12]],"date-time":"2018-01-12T10:27:54Z","timestamp":1515752874000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Plasmodium dihydrofolate reductase is a second enzyme target for the antimalarial action of triclosan"],"prefix":"10.1038","volume":"8","author":[{"given":"Elizabeth","family":"Bilsland","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liisa","family":"van Vliet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Williams","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jack","family":"Feltham","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marta P.","family":"Carrasco","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wesley L.","family":"Fotoran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eliana F. G.","family":"Cubillos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1724-0337","authenticated-orcid":false,"given":"Gerhard","family":"Wunderlich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morten","family":"Gr\u00f8tli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1367-6312","authenticated-orcid":false,"given":"Florian","family":"Hollfelder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Jackson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7208-4387","authenticated-orcid":false,"given":"Ross D.","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3410-6439","authenticated-orcid":false,"given":"Stephen G.","family":"Oliver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,1,18]]},"reference":[{"key":"19549_CR1","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1038\/nrd4573","volume":"14","author":"TN Wells","year":"2015","unstructured":"Wells, T. N., van Huijsduijnen, R. H. & Van Voorhis, W. C. Malaria medicines: a glass half full? Nature reviews. Drug discovery 14, 424\u2013442 (2015).","journal-title":"Nature reviews. Drug discovery"},{"key":"19549_CR2","doi-asserted-by":"publisher","first-page":"e105922","DOI":"10.1371\/journal.pone.0105922","volume":"9","author":"GC Melo","year":"2014","unstructured":"Melo, G. C. et al. Expression levels of pvcrt-o and pvmdr-1 are associated with chloroquine resistance and severe Plasmodium vivax malaria in patients of the Brazilian Amazon. PLoS One 9, e105922 (2014).","journal-title":"PLoS One"},{"key":"19549_CR3","doi-asserted-by":"publisher","first-page":"526","DOI":"10.1016\/j.chom.2015.02.011","volume":"17","author":"SA Mikolajczak","year":"2015","unstructured":"Mikolajczak, S. A. et al. Plasmodium vivax liver stage development and hypnozoite persistence in human liver-chimeric mice. Cell Host Microbe 17, 526\u2013535 (2015).","journal-title":"Cell Host Microbe"},{"key":"19549_CR4","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1038\/ng.3189","volume":"47","author":"O Miotto","year":"2015","unstructured":"Miotto, O. et al. Genetic architecture of artemisinin-resistant Plasmodium falciparum. Nature genetics 47, 226\u2013234 (2015).","journal-title":"Nature genetics"},{"key":"19549_CR5","doi-asserted-by":"crossref","unstructured":"Fairhurst, R.M. Understanding artemisinin-resistant malaria: what a difference a year makes. Current opinion in infectious diseases (2015).","DOI":"10.1097\/QCO.0000000000000199"},{"key":"19549_CR6","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1128\/AAC.03265-14","volume":"59","author":"M Chugh","year":"2015","unstructured":"Chugh, M. et al. Identification and deconvolution of cross-resistance signals from antimalarial compounds using multidrug-resistant Plasmodium falciparum strains. Antimicrob Agents Chemother 59, 1110\u20131118 (2015).","journal-title":"Antimicrob Agents Chemother"},{"key":"19549_CR7","doi-asserted-by":"crossref","unstructured":"Dunachie, S., Hill, A. V. & Fletcher, H. A. Profiling the host response to malaria vaccination and malaria challenge. Vaccine (2015).","DOI":"10.1016\/j.vaccine.2015.07.107"},{"key":"19549_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/1475-2875-12-418","volume":"12","author":"RE Howes","year":"2013","unstructured":"Howes, R. E. et al. Spatial distribution of G6PD deficiency variants across malaria-endemic regions. Malar J 12, 418 (2013).","journal-title":"Malar J"},{"key":"19549_CR9","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/S0196-6553(96)90017-6","volume":"24","author":"HN Bhargava","year":"1996","unstructured":"Bhargava, H. N. & Leonard, P. A. Triclosan: applications and safety. Am J Infect Control 24, 209\u2013218 (1996).","journal-title":"Am J Infect Control"},{"key":"19549_CR10","doi-asserted-by":"publisher","first-page":"12264","DOI":"10.1021\/acs.est.7b02839","volume":"51","author":"J Han","year":"2017","unstructured":"Han, J., Qiu, W., Campbell, E. C., White, J. C. & Xing, B. Nylon Bristles and Elastomers Retain Centigram Levels of Triclosan and Other Chemicals from Toothpastes: Accumulation and Uncontrolled Release. Environ Sci Technol 51, 12264\u201312273 (2017).","journal-title":"Environ Sci Technol"},{"key":"19549_CR11","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1038\/84612","volume":"7","author":"N Surolia","year":"2001","unstructured":"Surolia, N. & Surolia, A. Triclosan offers protection against blood stages of malaria by inhibiting enoyl-ACP reductase of Plasmodium falciparum. Nat Med 7, 167\u2013173 (2001).","journal-title":"Nat Med"},{"key":"19549_CR12","doi-asserted-by":"publisher","first-page":"923","DOI":"10.1002\/iub.237","volume":"61","author":"AP Singh","year":"2009","unstructured":"Singh, A. P., Surolia, N. & Surolia, A. Triclosan inhibit the growth of the late liver-stage of Plasmodium. IUBMB Life 61, 923\u2013928 (2009).","journal-title":"IUBMB Life"},{"key":"19549_CR13","doi-asserted-by":"publisher","first-page":"13106","DOI":"10.1074\/jbc.M112000200","volume":"277","author":"R Perozzo","year":"2002","unstructured":"Perozzo, R. et al. Structural elucidation of the specificity of the antibacterial agent triclosan for malarial enoyl acyl carrier protein reductase. J Biol Chem 277, 13106\u201313114 (2002).","journal-title":"J Biol Chem"},{"key":"19549_CR14","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1016\/j.bbrc.2007.04.113","volume":"358","author":"G Nicola","year":"2007","unstructured":"Nicola, G. et al. Discovery of novel inhibitors targeting enoyl-acyl carrier protein reductase in Plasmodium falciparum by structure-based virtual screening. Biochem Biophys Res Commun 358, 686\u2013691 (2007).","journal-title":"Biochem Biophys Res Commun"},{"key":"19549_CR15","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/S0020-7519(01)00111-4","volume":"31","author":"R McLeod","year":"2001","unstructured":"McLeod, R. et al. Triclosan inhibits the growth of Plasmodium falciparum and Toxoplasma gondii by inhibition of apicomplexan Fab I. Int J Parasitol 31, 109\u2013113 (2001).","journal-title":"Int J Parasitol"},{"key":"19549_CR16","doi-asserted-by":"publisher","first-page":"2163","DOI":"10.1016\/j.bmcl.2006.01.051","volume":"16","author":"JS Freundlich","year":"2006","unstructured":"Freundlich, J. S. et al. Synthesis and biological activity of diaryl ether inhibitors of malarial enoyl acyl carrier protein reductase. Part 2: 2\u2032-substituted triclosan derivatives. Bioorg Med Chem Lett 16, 2163\u20132169 (2006).","journal-title":"Bioorg Med Chem Lett"},{"key":"19549_CR17","doi-asserted-by":"publisher","first-page":"3009","DOI":"10.1016\/j.ejmech.2008.12.028","volume":"44","author":"V Frecer","year":"2009","unstructured":"Frecer, V., Megnassan, E. & Miertus, S. Design and in silico screening of combinatorial library of antimalarial analogs of triclosan inhibiting Plasmodium falciparum enoyl-acyl carrier protein reductase. Eur J Med Chem 44, 3009\u20133019 (2009).","journal-title":"Eur J Med Chem"},{"key":"19549_CR18","doi-asserted-by":"crossref","unstructured":"Baschong, W. et al. Triclosan is minimally effective in rodent malaria models. Nat Med 17, 33\u201334; author reply 34\u201335 (2011).","DOI":"10.1038\/nm0111-33"},{"key":"19549_CR19","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1016\/j.bmcl.2012.12.022","volume":"23","author":"JW Anderson","year":"2013","unstructured":"Anderson, J. W. et al. Novel diaryl ureas with efficacy in a mouse model of malaria. Bioorg Med Chem Lett 23, 1022\u20131025 (2013).","journal-title":"Bioorg Med Chem Lett"},{"key":"19549_CR20","doi-asserted-by":"publisher","first-page":"25436","DOI":"10.1074\/jbc.M701813200","volume":"282","author":"JS Freundlich","year":"2007","unstructured":"Freundlich, J. S. et al. X-ray structural analysis of Plasmodium falciparum enoyl acyl carrier protein reductase as a pathway toward the optimization of triclosan antimalarial efficacy. J Biol Chem 282, 25436\u201325444 (2007).","journal-title":"J Biol Chem"},{"key":"19549_CR21","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1080\/1062936X.2014.984628","volume":"26","author":"SP Kumar","year":"2015","unstructured":"Kumar, S. P., George, L. B., Jasrai, Y. T. & Pandya, H. A. Prioritization of active antimalarials using structural interaction profile of Plasmodium falciparum enoyl-acyl carrier protein reductase (PfENR)-triclosan derivatives. SAR QSAR Environ Res 26, 61\u201377 (2015).","journal-title":"SAR QSAR Environ Res"},{"key":"19549_CR22","doi-asserted-by":"publisher","first-page":"567","DOI":"10.1016\/j.chom.2008.11.001","volume":"4","author":"M Yu","year":"2008","unstructured":"Yu, M. et al. The fatty acid biosynthesis enzyme FabI plays a key role in the development of liver-stage malarial parasites. Cell Host Microbe 4, 567\u2013578 (2008).","journal-title":"Cell Host Microbe"},{"key":"19549_CR23","doi-asserted-by":"publisher","first-page":"506","DOI":"10.1111\/j.1462-5822.2008.01270.x","volume":"11","author":"AM Vaughan","year":"2009","unstructured":"Vaughan, A. M. et al. Type II fatty acid synthesis is essential only for malaria parasite late liver stage development. Cell Microbiol 11, 506\u2013520 (2009).","journal-title":"Cell Microbiol"},{"key":"19549_CR24","doi-asserted-by":"publisher","first-page":"120158","DOI":"10.1098\/rsob.120158","volume":"3","author":"E Bilsland","year":"2013","unstructured":"Bilsland, E. et al. Yeast-based automated high-throughput screens to identify anti-parasitic lead compounds. Open Biol 3, 120158 (2013).","journal-title":"Open Biol"},{"key":"19549_CR25","doi-asserted-by":"publisher","first-page":"e1320","DOI":"10.1371\/journal.pntd.0001320","volume":"5","author":"E Bilsland","year":"2011","unstructured":"Bilsland, E. et al. Functional expression of parasite drug targets and their human orthologs in yeast. PLoS Negl Trop Dis 5, e1320 (2011).","journal-title":"PLoS Negl Trop Dis"},{"key":"19549_CR26","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1534\/genetics.108.087080","volume":"179","author":"S Keppler-Ross","year":"2008","unstructured":"Keppler-Ross, S., Noffz, C. & Dean, N. A new purple fluorescent color marker for genetic studies in Saccharomyces cerevisiae and Candida albicans. Genetics 179, 705\u2013710 (2008).","journal-title":"Genetics"},{"key":"19549_CR27","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1002\/yea.1130","volume":"21","author":"MA Sheff","year":"2004","unstructured":"Sheff, M. A. & Thorn, K. S. Optimized cassettes for fluorescent protein tagging in Saccharomyces cerevisiae. Yeast 21, 661\u2013670 (2004).","journal-title":"Yeast"},{"key":"19549_CR28","doi-asserted-by":"publisher","first-page":"20141289","DOI":"10.1098\/rsif.2014.1289","volume":"12","author":"K Williams","year":"2015","unstructured":"Williams, K. et al. Cheaper faster drug development validated by the repositioning of drugs against neglected tropical diseases. J R Soc Interface 12, 20141289 (2015).","journal-title":"J R Soc Interface"},{"key":"19549_CR29","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1111\/j.1365-2958.2012.08019.x","volume":"84","author":"K Witmer","year":"2012","unstructured":"Witmer, K. et al. Analysis of subtelomeric virulence gene families in Plasmodium falciparum by comparative transcriptional profiling. Molec Microbiol 84, 243\u2013259 (2012).","journal-title":"Molec Microbiol"},{"issue":"Spec No","key":"19549_CR30","first-page":"211","volume":"2","author":"S Jenkins","year":"1989","unstructured":"Jenkins, S., Addy, M. & Newcombe, R. Toothpastes containing 0.3% and 0.5% triclosan. I. Effects on 4-day plaque regrowth. Am J Dent 2(Spec No), 211\u2013214 (1989).","journal-title":"Am J Dent"},{"key":"19549_CR31","first-page":"68","volume":"24","author":"S Srinivasan","year":"2013","unstructured":"Srinivasan, S. et al. Plaque triclosan concentration and antimicrobial efficacy of a new calcium carbonate toothpaste with 0.3% triclosan compared to a marketed 0.3% triclosan toothpaste. J Clin Dent 24, 68\u201372 (2013).","journal-title":"J Clin Dent"},{"key":"19549_CR32","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1038\/nchembio.118","volume":"4","author":"AL Hopkins","year":"2008","unstructured":"Hopkins, A. L. Network pharmacology: the next paradigm in drug discovery. Nat Chem Biol 4, 682\u2013690 (2008).","journal-title":"Nat Chem Biol"},{"key":"19549_CR33","doi-asserted-by":"publisher","first-page":"3345","DOI":"10.1021\/jm0600545","volume":"49","author":"D Tasdemir","year":"2006","unstructured":"Tasdemir, D. et al. Inhibition of Plasmodium falciparum fatty acid biosynthesis: evaluation of FabG, FabZ, and FabI as drug targets for flavonoids. J Med Chem 49, 3345\u20133353 (2006).","journal-title":"J Med Chem"},{"key":"19549_CR34","doi-asserted-by":"publisher","first-page":"2059","DOI":"10.1158\/0008-5472.CAN-04-3469","volume":"65","author":"E Navarro-Peran","year":"2005","unstructured":"Navarro-Peran, E. et al. The antifolate activity of tea catechins. Cancer Res 65, 2059\u20132064 (2005).","journal-title":"Cancer Res"},{"key":"19549_CR35","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1038\/nature14451","volume":"522","author":"B Baragana","year":"2015","unstructured":"Baragana, B. et al. A novel multiple-stage antimalarial agent that inhibits protein synthesis. Nature 522, 315\u2013+ (2015).","journal-title":"Nature"},{"key":"19549_CR36","doi-asserted-by":"publisher","first-page":"3099","DOI":"10.1016\/0006-2952(73)90196-2","volume":"22","author":"Y Cheng","year":"1973","unstructured":"Cheng, Y. & Prusoff, W. H. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. Biochemical pharmacology 22, 3099\u20133108 (1973).","journal-title":"Biochemical pharmacology"},{"key":"19549_CR37","doi-asserted-by":"publisher","first-page":"1140","DOI":"10.1124\/mol.54.6.1140","volume":"54","author":"DA Fidock","year":"1998","unstructured":"Fidock, D. A., Nomura, T. & Wellems, T. E. Cycloguanil and its parent compound proguanil demonstrate distinct activities against Plasmodium falciparum malaria parasites transformed with human dihydrofolate reductase. Molecular pharmacology 54, 1140\u20131147 (1998).","journal-title":"Molecular pharmacology"},{"key":"19549_CR38","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1126\/science.781840","volume":"193","author":"W Trager","year":"1976","unstructured":"Trager, W. & Jensen, J. B. Human malaria parasites in continuous culture. Science 193, 673\u2013675 (1976).","journal-title":"Science"},{"key":"19549_CR39","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1128\/AAC.48.5.1803-1806.2004","volume":"48","author":"M Smilkstein","year":"2004","unstructured":"Smilkstein, M., Sriwilaijaroen, N., Kelly, J. X., Wilairat, P. & Riscoe, M. Simple and inexpensive fluorescence-based technique for high-throughput antimalarial drug screening. Antimicrob Agents Chemother 48, 1803\u20131806 (2004).","journal-title":"Antimicrob Agents Chemother"},{"key":"19549_CR40","doi-asserted-by":"publisher","first-page":"13046","DOI":"10.1073\/pnas.0501747102","volume":"102","author":"P Kongsaeree","year":"2005","unstructured":"Kongsaeree, P. et al. Crystal structure of dihydrofolate reductase from Plasmodium vivax: pyrimethamine displacement linked with mutation-induced resistance. Proc Natl Acad Sci USA 102, 13046\u201313051 (2005).","journal-title":"Proc Natl Acad Sci USA"},{"key":"19549_CR41","doi-asserted-by":"publisher","first-page":"16823","DOI":"10.1073\/pnas.1204556109","volume":"109","author":"Y Yuthavong","year":"2012","unstructured":"Yuthavong, Y. et al. Malarial dihydrofolate reductase as a paradigm for drug development against a resistance-compromised target. Proc Natl Acad Sci USA 109, 16823\u201316828 (2012).","journal-title":"Proc Natl Acad Sci USA"},{"key":"19549_CR42","doi-asserted-by":"publisher","first-page":"3585","DOI":"10.1016\/j.bmc.2011.03.067","volume":"19","author":"X Zhang","year":"2011","unstructured":"Zhang, X. et al. Design, synthesis, biological evaluation and X-ray crystal structure of novel classical 6,5,6-tricyclic benzo[4,5]thieno[2,3-d]pyrimidines as dual thymidylate synthase and dihydrofolate reductase inhibitors. Bioorg Med Chem 19, 3585\u20133594 (2011).","journal-title":"Bioorg Med Chem"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-19549-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-19549-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-19549-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T01:13:16Z","timestamp":1671585196000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-19549-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1,18]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["19549"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-19549-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,1,18]]},"assertion":[{"value":"22 September 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 December 2017","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 January 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare that they have no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"1038"}}